ADCC phenomenon is triggered by cetuximab, an anti EGFR antibody, which is widely used in cancer immunotherapy, including also locally advanced or recurrent/metastatic HNSCC treated with platinum-based chemotherapy plus cetuximab or panitumumab. This evidence concerns the gene EGFR and cancer.